Walnut Creek, CA, United States of America

Ricaredo Matanguihan

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent. Top assignee: Bayer Corporation. Active years: 2002.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ricaredo Matanguihan: Innovator in Cell Culture Technology

Introduction

Ricaredo Matanguihan is a notable inventor based in Walnut Creek, CA (US). He has made significant contributions to the field of cell culture technology, particularly in the development of methods that enhance the growth of mammalian cells.

Latest Patents

Matanguihan holds a patent for a process and medium for mammalian cell culture under low dissolved carbon dioxide concentration. This innovative cell culture medium contains less than about 1 g/L added sodium bicarbonate and includes an organic buffer and a metal complexing agent. The medium is preferably essentially free of added sodium bicarbonate. His methods of use of the medium are particularly beneficial for culturing mammalian cells, especially those engineered to produce recombinant factor VIII.

Career Highlights

Ricaredo Matanguihan is currently employed at Bayer Corporation, where he continues to advance research in cell culture technologies. His work has been instrumental in improving the efficiency and effectiveness of mammalian cell cultures.

Collaborations

One of his notable coworkers is Eva Sajan, with whom he collaborates on various projects related to cell culture and biotechnology.

Conclusion

Ricaredo Matanguihan's innovative work in cell culture technology exemplifies the impact of scientific research on biotechnology. His contributions are paving the way for advancements in the production of important biological products.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…